← Syndax Pharmaceuticals Inc
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||
| Current assets: | |||||||||||
| Cash and Cash Equivalents, at Carrying Value | $23.8m | $35.2m | $33.8m | $24.6m | $115.2m | $222.0m | $74.4m | $295.4m | $154.1m | $134.9m | |
| Prepaid Expense and Other Assets, Current | $3.0m | $3.4m | $2.3m | $2.6m | $5.7m | $8.3m | $1.9m | $3.3m | $8.5m | $13.5m | |
| Short-term Investments | $81.5m | $94.8m | $47.1m | $35.2m | $177.8m | $218.0m | $401.4m | $275.3m | $418.8m | $259.1m | |
| Inventory, Net | — | — | — | — | — | — | — | $0 | $366k | $32.8m | |
| Assets, Current | $108.5m | $133.4m | $83.3m | $62.3m | $298.9m | $448.4m | $489.8m | $580.9m | $603.1m | $528.1m | |
| Property, Plant and Equipment, Net | $260k | $267k | $373k | $281k | $192k | $278k | $20k | $8k | $0 | $181k | |
| Operating Lease, Right-of-Use Asset | — | — | — | $716k | $290k | $983k | $1.0m | $1.5m | $2.0m | $1.3m | |
| Other Assets, Noncurrent | $243k | $231k | $219k | $197k | $1.3m | — | $807k | $463k | $0 | — | |
| Additional Financial Items | |||||||||||
| Accounts Receivable, after Allowance for Credit Loss, Current | — | — | — | — | — | — | — | — | $7.6m | $38.0m | |
| AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax | $56k | ($143k) | ($25k) | — | ($4k) | $45k | ($806k) | $218k | $163k | $452k | |
| Assets | $109.0m | $137.2m | $83.9m | $63.5m | $300.6m | $449.7m | $497.2m | $612.9m | $724.8m | $529.7m | |
| LIABILITIES AND EQUITY | |||||||||||
| Current liabilities: | |||||||||||
| Operating Lease, Liability, Current | — | — | — | $478k | $316k | $361k | $434k | $1.0m | $471k | $470k | |
| Accounts Payable, Current | $2.4m | $2.2m | $1.4m | $6.2m | $3.5m | $5.7m | $4.3m | $10.0m | $11.6m | $16.6m | |
| Operating Lease, Liability, Noncurrent | — | — | — | $419k | $101k | $711k | $709k | $578k | $1.6m | — | |
| Deferred Revenue, Current | $1.2m | $1.6m | — | — | — | — | — | — | — | — | |
| Deferred Revenue, Noncurrent | $14.2m | $16.8m | — | — | — | — | — | — | — | — | |
| Long-term Debt, Current Maturities | — | — | — | — | — | — | — | — | $337.9m | $350.0m | |
| Liabilities, Current | $10.4m | $15.8m | $16.1m | $18.4m | $18.9m | $20.7m | $29.1m | $58.1m | $103.5m | $120.1m | |
| Other Liabilities, Noncurrent | $288k | $310k | $136k | $5k | $1k | — | — | — | — | — | |
| Liabilities | $24.9m | $32.9m | $30.9m | $31.9m | $48.4m | $41.3m | $29.8m | $58.7m | $436.7m | $465.1m | |
| Stockholders’ equity: | |||||||||||
| Preferred Stock, Value, Issued | $0 | — | — | — | — | $0 | $0 | $0 | $0 | $0 | |
| Common Stock, Value, Issued | $2k | $2k | $2k | $3k | $5k | $6k | $7k | $8k | $9k | $9k | |
| Retained Earnings (Accumulated Deficit) | ($305.3m) | ($366.1m) | ($439.4m) | ($495.5m) | ($568.6m) | ($543.7m) | ($693.0m) | ($902.4m) | ($1.2b) | ($1.5b) | |
| Additional Paid in Capital, Common Stock | $389.4m | $470.6m | $492.5m | $527.1m | $820.8m | $952.0m | $1.2b | $1.5b | $1.5b | $1.6b | |
| Stockholders' Equity Attributable to Parent | $84.1m | $104.3m | $53.0m | $31.6m | $252.2m | $408.4m | $467.4m | $554.2m | $288.1m | $64.6m | |
| Liabilities and Equity | $109.0m | $137.2m | $83.9m | $63.5m | $300.6m | $449.7m | $497.2m | $612.9m | $724.8m | $529.7m |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.